LabConnect Appoints Stephen Lesser as SVP, General Counsel

Johnson City, TN, August 1, 2025 – LabConnect is pleased to announce the appointment of Stephen Lesser, Esq., as LabConnect’s new SVP, General Counsel, effective Monday, August 4, 2025. Stephen joins LabConnect with nearly two decades of legal experience advising senior executives at life sciences and technology companies on all aspects of corporate legal matters and governance to support their innovation and growth strategies.

Before joining LabConnect, Stephen founded Tairbhe Ventures, a consulting firm supporting corporate strategy, business development and complex transactions in the life sciences space. Previously, he served as Principal and Lead Counsel for NovaQuest Capital Management, where he advised on product finance transactions, equity investments, and portfolio management activities for pre-clinical, clinical, and commercial stage biopharma companies. Additionally, Stephen served as Lead Counsel for Leaps by Bayer, Bayer’s corporate venture capital team, as Counsel for Bayer U.S., and as an associate at Troutman Pepper Locke.

“Stephen brings the exact legal and strategic acumen we need at this stage of our growth,” said Wes Wheeler, LabConnect Chief Executive Officer. “His experience and proven ability to navigate complex business environments will be instrumental as we scale, ensuring our legal function will be a true driver of operational excellence and innovation.”

As General Counsel, Stephen will oversee all corporate legal matters, including business strategy, contracts, M&A, governance, and regulatory compliance, to support LabConnect’s continued growth.

About LabConnect

LabConnect is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases.

LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.

Learn more at www.labconnect.com and follow on LinkedIn.